Half a Loaf is Not Good Enough

President George W. Bush announced on Aug. 9 in a nationally televised address to the nation that he had decided to restrict public funding for embryonic stem cell research to only those cell lines already in existence as of that day. He said at the time that there were 60 cell lines in existence around the world and that these should prove adequate to allow embryonic stem cell research to proceed (See also, "Stem Cells: Steady Momentum for Funding"). He also made it very clear that he would opp

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Bush's position was presented as a compromise. And many in the media, in the religious community, and in high political office accepted it as such. So have many in bioethics.

The Bush compromise is no compromise. It is an absolute ban on embryonic stem cell research. The cells lines that exist are not readily available for research. And if the president is to be taken at his word, he will oppose any derivation of new cell lines. Does anyone in the scientific community really believe that it will be possible to see what human embryonic stem cells can do in the battle against disease and disability using the cell lines that currently exist? And if not, why aren't those in leadership positions saying so loudly and clearly?

Existing cell lines will never be adequate to see what the potential is of human embryonic stem cells. Many of the cell lines ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Arthur Caplan

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo